| 项目编号 |
PRJCA018240 |
| 项目标题 |
Tislelizumab plus cetuximab and irinotecan in patients with previously treated MSS and RAS wild-type advanced colorectal cancer |
| 涉及领域 |
colorectal cancer |
| 数据类型 |
Raw sequence reads
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with cetuximab plus irinotecan for patients with relapsed or refractory colorectal cancer with RAS wild-type. Patients with RAS wild-type colorectal cancer who had failed at least 2 prior lines of systematic therapy including chemotherapy (oxaliplatin, irinotecan, fluoropyrimidines) with or without targeted agents (cetuximab, bevacizumab) will be recruited in this study. NGS and immune-related proteins test in blood samples obtained before treatment, 4 weeks after the first administration, first assessment at 8 weeks, and at progression aim to assess exploratory predictive biomarkers. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2024-06-01 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 39179622
|
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
|
Nature Communications
|
10.1038/s41467-024-51536-x
|
2024
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Zhongshan Hospital Affiliated to Fudan University
|
|
2020ZSLC02
|
|
|
|
| 提交者 |
Ji
He (he.ji@genecast.com.cn)
|
| 提交单位 |
Company Name: Genecast Biotechnology Co., Ltd |
| 提交日期 |
2023-07-10 |
